Compare Pfizer Inc (PFE) vs Texas Instruments Incorporated (TXN) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

Texas Instruments (TXN) trades at $284.07, showing minimal daily movement. The stock exhibits a mixed technical picture with a bearish moving average signal but oversold RSI levels. Fundamentally, revenue rebounded to $17.68B in 2025 with strong net margins of 29.11%, though recent quarters show inconsistent earnings beats. Analyst consensus remains positive with a $314.27 price target, supported by ongoing dividend payments and leadership transition news.

Outlook balances solid profitability and AI-driven demand potential against high valuation multiples and rising debt levels. Key opportunities include margin expansion from 300mm capacity and data center growth, while risks involve competitive pressures and execution of the new CFO. The stock presents a hold case for dividend investors but requires monitoring for sustained earnings improvement.